← Back to search
VEDANTA BIOSCIENCES, INC.
CAMBRIDGE, MA, 02139
UnclaimedClaim this profile (free)
Small Business
Prime contracting experience
1 record from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS. | — | $99,146,088 | Jul 21, 2026 | Sep 28, 2020 – Aug 31, 2027 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
1 record from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | ANTIBIOTIC RESISTANCE IS A GROWING PUBLIC HEALTH CONCERN WORSENED BY THE LACK OF EFFECTIVE ANTIMICROBIAL THERAPIES TO TREAT INFECTIONS WITH MULTIDRUG-RESISTANT ORGANISMS (MDRO). OF THESE, CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE), EXTENDED-SPECTRUM BETA LACTAMASE PRODUCERS (ESBL), AND VANCOMYCIN-RESISTANT ENTEROCOCCI (VRE) ARE BECOMING INCREASINGLY PREVALENT IN HOSPITALS WORLDWIDE AND ARE EXTREMELY CHALLENGING TO TREAT. INFECTIONS WITH THESE ORGANISMS CAN RESULT IN LIFE-THREATENING TREATMENT DELAYS OR DEATH AND RESULT IN APPROXIMATELY $2 BILLION HEALTHCARE-ASSOCIATED COSTS DUE TO PATIENT ISOLATION PRACTICES ALONE. CURRENT TREATMENT OPTIONS RELY ON ANTIBIOTICS THAT ARE TOXIC, LIMITED IN SPECTRUM AND FOR WHICH RESISTANCE HAS ALREADY EMERGED. BECAUSE OF THIS, NOVEL STRATEGIES TO TARGET INFECTIONS WITH THESE ORGANISMS AND CURB THE EMERGENCE OF ANTIBIOTIC RESISTANCE ARE URGENTLY NEEDED. INTESTINAL MDRO COLONIZATION HAS BEEN SHOWN TO PRECEDE INFECTION IN HIGHLY SUSCEPTIBLE PATIENT POPULATIONS AND IT IS ASSOCIATED WITH POOR OUTCOME. DECOLONIZATION STRATEGIES SUCH AS FECAL MICROBIOTA TRANSPLANTATION (FMT) HAVE BEEN SUCCESSFUL IN ELIMINATING THE INTESTINAL MDRO RESERVOIR, RESULTING IN SIGNIFICANTLY LOWER MDRO INFECTION RATES. THEREFORE, DECOLONIZATION OF HIGHLY ANTIBIOTIC-RESISTANT BACTERIA USING MICROBIOME-BASED APPROACHES OFFERS A NOVEL AND PROMISING ALTERNATIVE TO CURRENT INFECTION THERAPIES. VEDANTA BIOSCIENCES IS A CLINICAL-STAGE MICROBIOME COMPANY PIONEERING THE DEVELOPMENT OF LIVE BIOTHERAPEUTIC PRODUCTS (LBPS) CONSISTING OF PRECISELY-DEFINED AND WELL-CHARACTERIZED BACTERIAL CONSORTIA FOR THE TREATMENT OF INFLAMMATORY AND INFECTIOUS DISEASES. VEDANTA IS ADDRESSING THE CRITICAL NEED FOR NOVEL THERAPEUTICS TO PREVENT MDRO INFECTION BY DEVELOPING VE707, AN ORALLY ADMINISTERED INVESTIGATIONAL LBP CONSISTING OF DEFINED, WELL-CHARACTERIZED, BENEFICIAL GUT BACTERIA. VE707 IS PRODUCED FROM PURE, CLONAL BACTERIAL CELL BANKS, WHICH YIELD A PRODUCT OF UNIFORM COMPOSITION AND FREE OF ANY PATHOGENIC STRAINS, BYPASSING THE NEED TO RELY ON FECAL DONOR MATERIAL WITH INCONSISTENT COMPOSITION. VE707 IS DESIGNED TO DECOLONIZE GUT-DWELLING MDROS IN PATIENTS AT HIGH RISK FOR DEVELOPING INFECTIONS. SPECIFICALLY, VE707 IS BEING DEVELOPED TO ELIMINATE INTESTINAL CARRIAGE OF CRE, ESBL AND VRE TO PREVENT INFECTIONS WITH THESE ORGANISMS, RESTORE A HEALTHY MICROBIOTA, AS WELL AS PREVENT COLONIZATION RECURRENCE. KC3481 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $2,601,928 | Dec 9, 2022 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.